Dose-modified R-CODOX-M / R-IVAC: high-risk reference without proven CNS disease (eviQ 4489/4490)

Vue déterministe de l'entité source de la LJAM. L'autorité clinique demeure avec les ID de la source cités et l'état d'approbation de l ́examinateur.

Contenu clinique provisoire : il ne s'agit pas d'une ordonnance. Un oncologue doit vérifier les sources originales, l'applicabilité et le statut de révision.

Source YAML: dossier complet

Composantes	Aucune déclaration

ID	`REG-CODOX-M-IVAC`
Type	Protocole thérapeutique
État	pending_clinical_signoff
Maladies	Aucune déclaration
Sources	`SRC-EVIQ-BURKITT-CODOX-4489` `SRC-EVIQ-BURKITT-IVAC-4490` `SRC-EVIQ-BURKITT-OVERVIEW-3727` `SRC-EVIQ-CODOX-PATIENT-4489` `SRC-EVIQ-IVAC-PATIENT-4490` `SRC-EVIQ-MOUTH-PATIENT-3099` `SRC-EVIQ-TLS-108` `SRC-NCCN-BCELL-2025`

Notes

Scoped reference schedule repair based on eviQ 4489 v1 and 4490 v2, for high-risk Burkitt WITHOUT proven CNS disease. This is not original Magrath or LMB and not a universal Burkitt/CNS prescription. The indication now requires explicit high-risk and CNS-negative confirmation. Risk classification, broader eligibility, ranking and other protocol variants still require separate audits. Age, fitness, efficacy, availability and patient watchpoints are not validated by this repair. Mesna schedules may vary by institution. Intrathecal procedures must remain separate from IV drug administration; vincristine must NEVER be administered intrathecally.

Utilisé par

Indication

IND-BURKITT-1L-CODOXM-IVAC - IND-BURKITT-1L-CODOXM-IVAC

Suivi

MON-CODOX-IVAC-REGIMEN - Modified R-CODOX-M / R-IVAC block-specific reference monitoring